Z583

Z583 (GLXC-26150) is a chemical compound which acts as a potent and highly selective inhibitor of JAK3, and was developed for the treatment of rheumatoid arthritis.[1][2][3][4][5]

Z583
Identifiers
  • N-[3-[[6-[[1-(2-methoxyethyl)pyrazol-4-yl]amino]pyrazolo[3,4-d]pyrimidin-1-yl]methyl]phenyl]prop-2-enamide
CAS Number
PubChem CID
Chemical and physical data
FormulaC21H22N8O2
Molar mass418.461 g·mol−1
3D model (JSmol)
  • COCCN1C=C(C=N1)NC2=NC=C3C=NN(C3=N2)CC4=CC(=CC=C4)NC(=O)C=C
  • InChI=1S/C21H22N8O2/c1-3-19(30)25-17-6-4-5-15(9-17)13-29-20-16(11-24-29)10-22-21(27-20)26-18-12-23-28(14-18)7-8-31-2/h3-6,9-12,14H,1,7-8,13H2,2H3,(H,25,30)(H,22,26,27)
  • Key:BOBFKXIKGHTPJB-UHFFFAOYSA-N

See also

References
  1. Baillache DJ, Unciti-Broceta A. Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. RSC Med Chem. 2020 Sep 8;11(10):1112-1135. doi:10.1039/d0md00227e PMID 33479617
  2. Chen C, Yin Y, Shi G, Zhou Y, Shao S, Wei Y, Wu L, Zhang D, Sun L, Zhang T. A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine-related JAK-STAT signal. Sci Adv. 2022 Aug 19;8(33):eabo4363. doi:10.1126/sciadv.abo4363 PMID 35984890
  3. Phillips, R. Novel JAK3-specific inhibitor safe and effective in mouse RA model. Nat Rev Rheumatol 2022; 18: 551. doi:10.1038/s41584-022-00839-8
  4. Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, Bao Z, Lu J, Li L. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023 May 19;8(1):204. doi:10.1038/s41392-023-01468-7 PMID 37208335
  5. Jensen LT, et al. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors. eBioMedicine 2023; 97: 104840. doi:10.1016/j.ebiom.2023.104840
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.